India's parliamentary panel suggests free cancer treatment as drugmakers step up action

13 December 2022

Indian pharmaceutical companies are on an acquisition spree after a decade of caution and organic growth. And their main target appears to be cancer drugs. As patient numbers continue to rise, the country's Parliamentary panel has also called for free cancer treatment to middle-class households through a government-funded health insurance scheme, reports The Pharma Letter’s India correspondent.

Recently, four major anti-cancer drugs were added to India's National List of Essential Medicines (NLEM), with an official noting that the government is also looking to rationalize trade to make common cancer medicines more affordable.

With India’s cancer burden set to grow to over 1.5 million cases by 2025, the powers-that-be are keen to roll out more cancer treatments.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK